New Approaches To Treat Castrate-Resistant Prostate Cancer (CRCP)

Dr. Martin Gleave of the Vancouver Prostate Center in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP).

The lecture was given during the 24th Annual Congress of the European Association of Urology in Stockholm, Sweden.

Prostate Cancer | Cancer of Prostate - Incidence, Prevention, Causes, Symptoms & Treatment
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can help both in early detection and effective treatment

"If we look at the way kidney cancer treatment has changed over recent years we see a glimpse of the future", says Dr Gleave, "Targeted therapies may become available".

Recent studies indicate that tumor cells can develop an ability to synthesize enzymes to produce their own androgens for androgen receptor (AR) activation after castration. CRPC tumors are not uniformly hormone resistant and may remain sensitive to therapies directed against the ARs. Dr Gleave: "Several new classes of AR-targeting agents are now in clinical development, including the 2nd generation anti-androgen MDV3100, abiraterone, and Hsp27 (OGX-427)".

The growth of new blood vessels, angiogenesis, plays an essential role in prostate cancer development and metastasis. "Among the various angiogenic targets implicated in tumor angiogenesis, vascular endothelial growth factor (VEGF), a potent angiogenic growth factor, and its receptor have evoked a lot of interest," according to Dr Gleave. Bevacizumab targets VEGF and is a promising angiogenesis inhibitor in this indication. Other agents in late stage trials include sunitinib.

SPCG-4 Trial: Update On Watchful Waiting Versus Radical Prostatectomy
In 2005, the Scandinavian Prostate Cancer Group Study 4 (SPCG-4) reported that radical prostatectomy improved prostate cancer survival compared with watchful...

Clusterin is a stress-induced, multi-functional, molecular chaperone. A novel, phase I pre-prostatectomy trial defined the optimal biologically dose and toxicity parameters of OGX-011 with maximal knockdown of clusterin in prostate and lymph node tissues at the 640 mg dose level. A phase II study includes 81 men with CRPC to receive either docetaxel and OGX-11 (n=40) or docetaxel alone (n=41).

"All in all, we need to move forward with the momentum and continue to let biology guide treatment developments", said Gleave, who also expressed his gratitude for being invited to speak at the 24th Annual EAU Congress.

Selected Men With Low-risk Prostate Cancer Can Be Safe Without Immediate Treatment
Some men diagnosed with low-risk prostate cancer, opting not to initially receive treatment can be safe if they are closely monitored.

Source-Eurekalert
ARU/L